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Previous studies (1, 2) have revealed that the virus of human in- 
fluenza is capable of infecting mice and ferrets only when introduced 
into the respiratory tract.  When mice are inoculated subcutaneously 
or intraperitoneaUy infection does not occur, but with repeated in- 
oculations in this manner the animals develop an active resistance to 
infection by the respiratory route.  Similarly, though to a somewhat 
less  extent,  ferrets,  while  exhibiting no  evidence of  infection from 
subcutaneous injections of active virus, develop circulating antibodies 
and increased resistance to the virus introduced by way of the nasal 
passages. 
Because of the significance of these observations as a possible guide 
toward preventive measures, it was important to determine the effects 
of the introduction of untreated active virus in human individuals. 
The use of animal tissues as the source of virus for human study is 
accompanied by certain undesirable features, such as the possibility 
of protein sensitization, or the introduction of bacterial or extraneous 
virus contaminants.  In order to eliminate these difficulties, the virus 
derived from infected mouse lungs was introduced into tissue culture 
medium.  The medium  was  that  described by  Li  and  Rivers  (3), 
which consists of minced chick embryo suspended in Tyrode's solution. 
Under these conditions the virus multiplied readily (4,  5)  and has 
been carried through 160 subcultures in 11 months.  The culture virus 
maintains its capacity to infect mice and ferrets by intranasal inocula- 
tion and also to induce immunity in these animals when administered 
by subcutaneous and intraperitoneal routes.  It was employed for the 
work described in the present paper.  This embodies the results of 
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titrations of the capacity of the serum of 22 human individuals, before 
and at intervals up to 5 months after vaccination, to neutralize approx- 
imately 1000 lethal doses of the mouse passage human  influenza virus 
as measured by mouse protection tests. 
EXPERLHENTAL 
The  results  of  studies  of  Andrewes,  Laidlaw,  and  Smith  (6)  in 
England and those of Francis and Magill (7) in the United States have 
shown by mouse protection tests that the serum of a  high percentage 
of individuals of all ages possesses the capacity to neutralize the human 
influenza  virus.  In  order  to  test  the  effect  of  vaccination,  it  was 
necessary to select so far as possible subjects whose serum beforehand 
possessed the least neutralizing capacity. 
From 60 available  volunteers,  23  were chosen for the test.  All but  5 were 
medical  students in the third decade  of life.  The others  ranged from 35 to 64 
years of age.  The supernatant fluid of cultures  made as above described  from 
which  the cells had been  removed by centrifugation  at low speed, was used  for 
vaccination.  To 11 of the subjects  doses of 0.5 cc., 1.0 cc., and  1.0 cc., respec- 
tively, were given subcutaneously  at weekly intervals,  and after a further interval 
of 2 to 3 weeks an additional  dose of 2.0 cc. of the virus-containing  fluid was given 
by the same  route.  To 5 individuals  doses of  1.0  cc., 1.0 cc., and 2.0 cc., re- 
spectively, were given subcutaneously  at weekly intervals.  The remaining 7 sub- 
jects were given three successive doses of 0.5 cc. of culture virus intradermally at 
weekly intervals. 
A sample of serum was obtained from each subject before vaccination,  before 
each subsequent  injection, and 10 days after the final injection  (8).  Where possi- 
ble, serum was again obtained  from each volunteer 2 and 5 months after the final 
vaccinating  dose of virus. 
The virus used  in  the protection tests  was  the mouse  passage  Puerto  Rico 
8 strain.  The virus  was obtained from the lungs of infected  mice, which were 
ground and suspended  in  10 per cent normal horse  serum  in  physiological  salt 
solution.  After centrifugation  at 2000 revolutions per minute for 15 minutes,  the 
supernatant fluid was diluted  to a 2 per cent virus  concentration.  Each serum 
was tested undiluted and in dilutions  of 1:5, 1:10,  1:20, 1:40, 1:80,  and 1:160. 
Serum dilutions were made with physiological saline.  To each serum dilution was 
added an equal quantity of 2'per cent virus suspension; the mixture was incubated 
at 37°C. for 30 minutes;  and 3 mice were then inoculated  intranasally  with 0.03 
cc. of the mixture.  The 4 specimens of serum taken at various  times from the 
same individual  were subjected  to test at the same time, and usually those from 
4 individuals  were  tested  together.  As a  control,  the serum  of one  individual 
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Each was terminated  on  the 7th  day after  infection: all surviving mice were 
autopsied then and the extent of the pulmonary involvement was recorded,  The 
titer of the serum was estimated as the greatest dilution which resulted in a 50 
per cent  survival  of the mice throughout  this period.  Mice which presented 
extensive lung lesions at autopsy on the 7th day were considered, however, not 
to have been protected. 
RESULTS 
The  results  were  uniform  in  that  the  serum  of  each  individual 
developed an increased capacity to neutralize  human influenza  virus 
as a  result of vaccination.  This increase is not a  slow, gradual  rise 
throughout  the  period  of vaccination.  On  the  contrary,  the  most 
significant rise in antibodies occurs rather abruptly in the 2nd week. 
The  serum  titrations  reveal  the  facts  that  the  antibody  levels  are 
highest immediately following the course of vaccination, that in gen- 
eral the same approximate concentration is maintained for 2 months, 
but that at 5 months a decline in titer is observed (Text-figs.  1, 2, 3). 
In spite of the fact that a decline in titer occurs, the residual titer of 
neutralizing antibodies in all but one instance remained at a level well 
above that of the original. 
While the same general trend prevailed in the entire series, consider- 
able variation occurred in the antibody response of different individ- 
uals.  The height of the titer attained and the rate of decline in titer 
with the passage of time seem to be functions of the individual subject. 
Nevertheless,  the  results  suggest  that  those  persons  whose  serum 
possessed the most antibody prior to vaccination responded to vaccina- 
tion  with  the  formation  of  less  additional  antibody  than  subjects 
whose original titer was quite low.  For comparison the sera of three 
patients who actually suffered from influenza (2) and their sera 3 weeks 
after recovery and again 5 months after recovery were titrated (Text- 
fig. 4).  In these  three cases a  sharp  antibody rise is evident after 3 
weeks' convalescence.  The  height of antibody in these cases is not 
strikingly  dissimilar  to  that  of the  vaccinated  group  (Text-fig.  5). 
Moreover, the same tendency to  decline after 5 months is observed, 
though perhaps to a less extent. 
The results in the group of individuals receiving vaccination by the 
intradermal route appear to follow the same general course as in those 
inoculated subcutaneously.  The mean titer of the serum of the former 254  VACCINATION  V~ITH VIRUS  OF  ~X.rg.AN INFLUENZA 
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TExT-FIGs. 1 and 2.  Antibody response to subcutaneous vaccination.  Each 
block represents the findings in a single individual  vaccinated by the subcutaneous 
route.  The  time interval between the first  vaccinating dose  of  virus and the 
date on which the serum was obtained, representing the  end of  the period of 
vaccination, was 40 days.  The time intervals are thus measured from the date 
on which vaccination was begun.  The titer of the serum is recorded in terms of 
final effective dilution. THOMAS ]~RANCIS, JR.,  AND T. P. MAGILL  255 
group  before vaccination  was  approximately  1:10.  It  increased  to 
about 1: 40, a fourfold increase.  The mean titer of the subcutaneously 
vaccinated  group  was  about  1:4  before  and  1:40  after,  a  tenfold 
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TEXT-FIG. 2 
increase  (Text-fig.  6).  Two modifying factors may play some  r61e 
in this result: first, the total amount of virus administered is smaller; 
second, these subjects had comparatively high original antibody titers. 256  VACCINATION  WITH  VIRUS  OF ~N  INFLUENZA 
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TEXT-FIe. 4.  Antibody response to natural infection.  The titer of the serum 
of 3 human individuals tested during the acute  phase of  influenza, 21  days and 
180 days later, respectively. 
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TEXT-FIG.  3.  Titers after subcutaneous vaccinations.  (Line connects means 
of groups.)  The solid line represents the geometrical mean of all tests with the 
sera of the subjects vaccinated by  the subcutaneous  route.  The  black circles 
represent  the  results  of  individual tests.  The  titers  of  the  control serum,  as 
measured in different tests, are enclosed in the left upper corner. 
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A bs¢..ce of Unfavorable Reactions Following Vaccination 
In addition to the knowledge obtained regarding  the development 
and persistence of antibodies following vaccination, it was important 
to determine wheth~- any ill effects were contributed by the introduc- 
tion  of untreated,  active  virus.  To  this  end  each  subject was  ad- 
mitted to the hospital isolation ward for 48 hours at the time of the 
first injection, and again at the time of the largest (2 cc.) dose.  Care- 
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ful isolation  precautions were observed, repeated temperatures  were 
taken,  all symptoms were recorded,  and examinations  of the  site of 
inoculation were made.  In those who received the virus subcutane- 
ously no significant elevation of temperature occurred, and the local 
reactions were inconstant  and extremely mild--frequently unnoticed 
by the  subject himself.  In  those who received virus intradermally 
more {mmediate erythematous reaction was observed at the site of in- 
jection,  but  no  unpleasant  features  occurred.  Furthermore,  two 
TExT-FzG. 5. Titers  after natural  infections.  (Line connects means of sub- 
cutaneous groups.)  The titers of the serum of 3 patients during the disease and 
up to 180 days after recovery are shown as black circles.  For comparison, a solid 
line is superimposed, representing the mean titers of the sera taken within a similar 
time period after the subcutaneous vaccination (see Text-fig. 3). 258  VACCINATION  WITH VIRUS OF HUMAN IIN"FLUENZA 
subjects  were  inoculated with  influenza virus  while  suffering from 
common  colds.  No  aggravation  of  symptoms  was  noted.  One 
subject was given but one dose of 3 cc. of tissue culture virus subcu- 
taneously.  After an asymptomatic interval of 48  hours, nasal and 
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TEXT-FIG. 6. Antibody response to intradermal vaccination. The  titer of 
serum of individuals, taken at intervals up to 180 days after beginning of vac- 
cinatinn by the intradermal route. 
pharyngeal washings were obtained to ascertain whether virus could 
be  recovered from the respiratory tract.  The  concentrated mucus 
was inoculated into the nose of a  normal ferret, which exhibited no 
evidence  of  infection,  nor  were  specific  antibodies  subsequently THOMAS I~RANCIS, JR.,  AND  T.  P.  MA.GILL  259 
demonstrable  in  the  ferret's  serum.  This  indicates,  of course,  that 
virus introduced  subcutaneously  does not readily find its way to the 
respiratory tract.  Furthermore,  Chenoweth et al. (9) have vaccinated 
a  large  group  of human  subjects with  influenza  virus obtained  from 
mouse lung.  In no instance was evidence of infection observed. 
SUMMARY 
Human  influenza  virus cultivated  in tissue  culture  medium may be 
administered subcutaneously or intradermally to human  individuals 
without causing evidence of infection. Subjects so treated devclop a 
good titcr  of circulating  antibodies effective  against mouse passage 
virus and, if antibodies were previously  present, vaccination stimu- 
lates the production of  more antibody.  The antibodies so induced 
persist  for at least  5 months, although in this  period of time some 
decline  in titer  may have begun.  The antibody response to vaccina- 
tion  parallels  both in  extent and persistence  that occurring as a result 
of the naturally acquired disease. 
The available data do not enable onc to evaluate the effect  of 
vaccination in prcventing human infection  with influenza.  It seems 
not unlikely that the increase  in circulating  antibody will  be accom- 
panied  by an  increased  ability  to  combat the  natural infection. 
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